Efficacy of once weekly teriparatide in patients with glucocorticoid-induced osteoporosis

Trial Profile

Efficacy of once weekly teriparatide in patients with glucocorticoid-induced osteoporosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Teriparatide (Primary) ; Alendronic acid
  • Indications Osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms TOWER-GO
  • Most Recent Events

    • 04 Jan 2017 Planned number of patients changed from 400 to 204.
    • 04 Jan 2017 Planned End Date changed from 31 Jul 2017 to 31 Jul 2018.
    • 04 Jan 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top